<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028938</url>
  </required_header>
  <id_info>
    <org_study_id>REBACDR0000069148</org_study_id>
    <secondary_id>CCCWFU-62299</secondary_id>
    <secondary_id>CCCWFU-BG01-193</secondary_id>
    <secondary_id>NCI-P01-0200</secondary_id>
    <nct_id>NCT00028938</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase III Randomized Trial Evaluating the Effect of Epoetin Alfa (Procrit) on Local Control in Patients Undergoing Concurrent Chemotherapy and Radiation Therapy for Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Epoetin alfa may stimulate red blood cell production and prevent or treat anemia in patients&#xD;
      who are undergoing radiation therapy and chemotherapy. It is not yet known if chemotherapy&#xD;
      combined with radiation therapy is more effective with or without epoetin alfa in treating&#xD;
      non-small cell lung cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to determine the effectiveness of chemotherapy combined&#xD;
      with radiation therapy with or without epoetin alfa in treating patients who have stage IIIA&#xD;
      or stage IIIB non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of epoetin alfa in maintaining hemoglobin levels in patients with&#xD;
           stage IIIA or IIIB non-small cell lung cancer when treated with chemoradiotherapy.&#xD;
&#xD;
        -  Compare the time to local and systemic progression in patients receiving&#xD;
           chemoradiotherapy with or without epoetin alfa.&#xD;
&#xD;
        -  Compare tumor response rate and overall survival in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Compare quality of life in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the number of transfusions in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      Karnofsky performance status (90-100% vs 60-80%), weight loss (no more than 5% vs 6-10%), and&#xD;
      baseline hemoglobin (women 11.0-12.4 g/dL and men 11.0-13.4 g/dL vs women 12.5-15.0 g/dL and&#xD;
      men 13.5-15.0 g/dL). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Beginning 7-10 days before the start of chemoradiotherapy, patients receive&#xD;
           epoetin alfa subcutaneously once weekly for 8 weeks. Patients receive paclitaxel IV over&#xD;
           1 hour and carboplatin IV over 30 minutes once weekly for 7 weeks. Patients undergo&#xD;
           radiotherapy 5 days a week for 7 weeks for a total of 33 treatments. Treatment continues&#xD;
           in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive paclitaxel, carboplatin, and radiotherapy as in arm I. Quality&#xD;
           of life is assessed at baseline, at completion of chemoradiotherapy, every 3 months for&#xD;
           1 year, every 4 months for 1 year, and then every 6 months for 3 years.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6&#xD;
      months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 202-232 patients (101-116 per treatment arm) will be accrued&#xD;
      for this study within 1.7-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2002</start_date>
  <completion_date type="Actual">November 10, 2002</completion_date>
  <primary_completion_date type="Actual">November 10, 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">1</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>epoetin alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed stage IIIA or IIIB non-small cell lung&#xD;
             cancer (NSCLC)&#xD;
&#xD;
               -  Squamous cell carcinoma&#xD;
&#xD;
               -  Adenocarcinoma (including bronchoalveolar cell)&#xD;
&#xD;
               -  Large cell anaplastic carcinoma (including giant and clear cell carcinomas)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin 11.0-15 g/dL&#xD;
&#xD;
          -  If hemoglobin is 11.0-11.9 g/dL then the following lab values are required:&#xD;
&#xD;
               -  Iron greater than 60 mcg/mL&#xD;
&#xD;
               -  Transferrin saturation greater than 20%&#xD;
&#xD;
               -  Ferritin at least 100 mg/mL&#xD;
&#xD;
               -  Iron binding capacity less than 400 mcg/dL&#xD;
&#xD;
               -  RBC folate normal&#xD;
&#xD;
               -  B12 normal&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  AST less than 2 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance at least 20 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV1 at least 0.8 L&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known hypersensitivity to mammalian cell-derived products or human albumin&#xD;
&#xD;
          -  No other concurrent or prior malignancy within the past 2 years except non- melanoma&#xD;
             skin cancers&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 30 days since prior transfusion&#xD;
&#xD;
          -  No prior epoetin alfa or experimental forms of epoetin alfa&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for NSCLC&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy for NSCLC&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 2 weeks since prior thoracotomy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent therapy for iron, folate, or B12 deficiency&#xD;
&#xD;
          -  No other concurrent anti-cancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur William Blackstock, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>June 30, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2003</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

